Logo image of BCT.CA

BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Overview

TSX:BCT - CA1079302081 - Common Stock

10.69 CAD
+0.59 (+5.84%)
Last: 8/29/2025, 7:00:00 PM

BCT.CA Key Statistics, Chart & Performance

Key Statistics
52 Week High3795
52 Week Low10.09
Market Cap20.10M
Shares1.88M
Float1.79M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-60.57
PEN/A
Fwd PEN/A
Earnings (Next)10-27 2025-10-27/amc
IPO10-12 2006-10-12
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


BCT.CA short term performance overview.The bars show the price performance of BCT.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

BCT.CA long term performance overview.The bars show the price performance of BCT.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BCT.CA is 10.69 CAD. In the past month the price decreased by -89.42%. In the past year, price decreased by -99.32%.

BRIACELL THERAPEUTICS CORP / BCT Daily stock chart

BCT.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EDT.CA SPECTRAL MEDICAL INC N/A 425.87M
FRX.CA FENNEC PHARMACEUTICALS INC N/A 343.98M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 266.82M
TH.CA THERATECHNOLOGIES INC N/A 204.61M
HBP.CA HELIX BIOPHARMA CORP N/A 103.88M
WLLW.CA WILLOW BIOSCIENCES INC N/A 97.56M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 90.92M
BLU.CA BLUENERGIES LTD N/A 82.42M
NRX.CA NUREXONE BIOLOGIC INC N/A 66.41M
COV.CA COVALON TECHNOLOGIES LTD 18.46 65.81M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 60.21M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 45.90M

About BCT.CA

Company Profile

BCT logo image Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Company Info

BRIACELL THERAPEUTICS CORP

Suite 300 - Bellevue Centre, 235 -15th Street

West Vancouver BRITISH COLUMBIA V7T 2X1 CA

CEO: William Williams

Employees: 17

BCT Company Website

BCT Investor Relations

Phone: 16049211810

BRIACELL THERAPEUTICS CORP / BCT.CA FAQ

What is the stock price of BRIACELL THERAPEUTICS CORP today?

The current stock price of BCT.CA is 10.69 CAD. The price increased by 5.84% in the last trading session.


What is the ticker symbol for BRIACELL THERAPEUTICS CORP stock?

The exchange symbol of BRIACELL THERAPEUTICS CORP is BCT and it is listed on the Toronto Stock Exchange exchange.


On which exchange is BCT.CA stock listed?

BCT.CA stock is listed on the Toronto Stock Exchange exchange.


What is BRIACELL THERAPEUTICS CORP worth?

BRIACELL THERAPEUTICS CORP (BCT.CA) has a market capitalization of 20.10M CAD. This makes BCT.CA a Nano Cap stock.


How many employees does BRIACELL THERAPEUTICS CORP have?

BRIACELL THERAPEUTICS CORP (BCT.CA) currently has 17 employees.


Should I buy BRIACELL THERAPEUTICS CORP (BCT.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BRIACELL THERAPEUTICS CORP (BCT.CA) stock pay dividends?

BCT.CA does not pay a dividend.


When does BRIACELL THERAPEUTICS CORP (BCT.CA) report earnings?

BRIACELL THERAPEUTICS CORP (BCT.CA) will report earnings on 2025-10-27, after the market close.


What is the Price/Earnings (PE) ratio of BRIACELL THERAPEUTICS CORP (BCT.CA)?

BRIACELL THERAPEUTICS CORP (BCT.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-60.57).


BCT.CA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BCT.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BCT.CA. While BCT.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BCT.CA Financial Highlights

Over the last trailing twelve months BCT.CA reported a non-GAAP Earnings per Share(EPS) of -60.57. The EPS decreased by -693.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -123.71%
ROE -321.51%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1093.94%
Sales Q2Q%N/A
EPS 1Y (TTM)-693.69%
Revenue 1Y (TTM)N/A

BCT.CA Forecast & Estimates


Analysts
Analysts80
Price TargetN/A
EPS Next Y67.23%
Revenue Next YearN/A

BCT.CA Ownership

Ownership
Inst Owners10.88%
Ins Owners0.35%
Short Float %N/A
Short RatioN/A